Peptides with evidence for improving slow-wave sleep or sleep architecture — ranked by mechanism and data quality.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Several peptides affect sleep indirectly through GH pulsatility, which correlates with slow-wave (deep) sleep. Direct sleep-quality trials in healthy adults are scarce. This guide ranks options by mechanistic plausibility and any controlled sleep-architecture data.
How we ranked: Ordered by: (1) polysomnography evidence, (2) GH-axis mechanism, (3) safety, (4) dosing convenience.
Orally active ghrelin agonist. Multiple human studies document increases in REM and stage 4 slow-wave sleep, particularly in older adults. Most direct sleep-architecture evidence in this class.
Short-acting GHSR agonist. Pre-sleep dosing aligns with natural GH pulse timing. Direct sleep-architecture trials are limited but mechanistic rationale is strong.
GHRH analog. Sermorelin (similar class) has been shown to restore GH pulse amplitude and may indirectly support slow-wave sleep in older adults with age-related GH decline.
Pineal-derived tetrapeptide with circadian-rhythm claims in Russian literature. Human sleep-architecture trials outside that research network are absent.
MK-677 has shown increases in REM and slow-wave sleep in published human trials, particularly in older adults. Other GH peptides have plausible mechanisms but less direct sleep-architecture data.
No peptide is FDA approved for insomnia. MK-677 has the most direct polysomnography evidence but carries other considerations (appetite, IGF-1 elevation). Peptides are not a first-line insomnia treatment.
Evening dosing aligns with the natural nocturnal GH pulse. Whether this timing improves sleep outcomes is not directly established in trials of CJC-1295 specifically.